- Active not recruitingPHASE3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.
For: Hidradenitis SuppurativaUnited States · Argentina · Australia - Active not recruitingPHASE3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
This study is looking at the long-term safety of a treatment called secukinumab for people with Polymyalgia Rheumatica (PMR). It's for those who have already been in a previous study for secukinumab and had their PMR symptoms come back after stopping treatment.
For: Polymyalgia RheumaticaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
For: Polymyalgia RheumaticaDenmark · Italy · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff problems. It compares the medicine to a dummy treatment (placebo) to see if it helps reduce pain and improve shoulder movement over 24 weeks.
For: Moderate to severe rotator cuff tendinopathyPortugal · Denmark · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff tendinopathy. Researchers want to see if it helps reduce pain and improve shoulder movement compared to a dummy medicine.
For: Moderate to severe rotator cuff tendinopathySpain · Hungary · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
For: Giant cell arteritis (GCA)Estonia · Sweden · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
This study looks at new ways to treat serious, ongoing inflammatory diseases that haven't responded to other treatments. Researchers are testing different existing medicines to see which ones work best to reduce inflammation and improve symptoms in patients with complex conditions.
For: Patients displaying a non-classified · severe and resistant inflammatory diseaseFrance - Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
This study investigates how inflammation, particularly involving a protein called IL-17, might link certain skin and joint conditions like psoriasis and psoriatic arthritis with depression. Researchers will use special brain scans and different anti-inflammatory medicines to understand and potentially improve depression symptoms.
For: Psoriatic Arthritis · Depression · Psoriatic PlaqueUnited Kingdom